Affiris starts Phase II trials of vaccine for Alzheimer's disease
This article was originally published in Scrip
Executive Summary
Vienna-based Affiris is starting Phase II clinical trials of its AD-02 vaccine candidate for Alzheimer's disease targeting beta-amyloid precursor protein after it completed its Phase I testing several months ago. The study should involve up to 420 patients in Austria and five other European countries (Croatia, the Czech Republic, Germany, France and Slovakia).
You may also be interested in...
Poland's new law fixes prices and trade mark-ups of reimbursed drugs
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
Global pharma boosts business in Russia - Why Russia (introduction)
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Medvedev wants talks on trials mutual recognition with US and EU
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.